Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pragmatic trial of preemptive pharmacogenetic testing to reduce statin musculoskeletal adverse reactions
2023-506814-31-01Phase 4Authorised
- Sponsor
- Fundación de Investigación Biomédica del Hospital Universitario de La Princesa
- Start
- Feb 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of atorvastatin, rosuvastatin, pravastatin, fluvastatin and pitavastatin in cardiac morbidity, hypercholesterolemia and familial hypercholesterolemia (FH) (2 arms), sponsored by Fundación de Investigación Biomédica del Hospital Universitario de La Princesa. Primary endpoint: Incidence of statin-induced musculoskeletal adverse reactions at 6 months. Planned start Feb 2024; status: authorised.
02
Drugs
atorvastatinrosuvastatinpravastatinfluvastatinpitavastatin
03
Conditions
cardiac morbidityhypercholesterolemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2023-506814-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506814-31-01.